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Abstract: The skin of most mammals is characterised by the
presence of sebaceous glands (SGs), whose predominant
constituent cell population is sebocytes, that is, lipid-producing
epithelial cells, which develop from the hair follicle. Besides
holocrine sebum production (which contributes 90% of skin
surface lipids), multiple additional SG functions have emerged.
These range from antimicrobial peptide production and
immunomodulation, via lipid and hormone synthesis/metabolism,
to the provision of an epithelial progenitor cell reservoir.
Therefore, in addition to its involvement in common skin diseases
(e.g. acne vulgaris), the unfolding diversity of SG functions, both
in skin health and disease, has raised interest in this integral
component of the pilosebaceous unit. This practical guide
provides an introduction to SG biology and to relevant SG
histochemical and immunohistochemical techniques, with
emphasis placed on in situ evaluation methods that can be easily
employed. We propose a range of simple, established markers,
which are particularly instructive when addressing specific SG
research questions in the two most commonly investigated species
in SG research, humans and mice. To facilitate the development
of reproducible analysis techniques for the in situ evaluation of
SGs, this methods review concludes by suggesting quantitative
(immuno-)histomorphometric methods for standardised SG
evaluation.
Key words: human – immunohistochemistry – mouse – quantification –
sebaceous gland
Accepted for publication 26 June 2013
Introduction
Interest in the sebaceous gland (SG) has long been overshadowed
by the prominent clinical role of this important skin appendage in
acne vulgaris (13). However, beyond the mere production of
sebum, the SG also possesses complex metabolic, (neuro)endocrine
and immunological functions (49) and acts in the context of the
skin neuroendocrine system (1016) to maintain and regulate local
homoeostasis (14,17). The SG is one of the most intriguing mam-
malian skin structures as it can serve as a model for studying
numerous central life sciences issues, for example in cell biology
and in skin, lipid or hormone research (1822). Moreover, the SG
is unique in at least two ways: its main cellular component, sebo-
cytes, is of epithelial origin, yet engage in lipid production and
metabolism, a feature usually associated with adipocytes; and
sebum is produced by holocrine secretion, that is, via an unusual
mode of cell suicide that sebocytes undergo (21,2325).
Whilst there are many reviews on SG biology and function
(8,18,20,22,2629), there are no recent methodological reviews, tar-
geted to newcomers, which explain how to professionally examine
the SG in situ. Therefore, this review provides a succinct introduc-
tion into essentials of SG biology and offers hands-on guidance for
beginners in SG research on relevant in situ evaluation methods,
focussing on histochemistry and immunohistochemistry of human
and murine SGs; the two most commonly investigated species in
SG research.
Just as concerted efforts are being made to develop a universal
grading scale for the clinical presentation of the main SG disorder,
acne vulgaris (30), it is equally important to develop standardised
techniques for the histological evaluation of SG parameters in
human and murine skin. Therefore, we also encourage the stan-
dardisation of histomorphometric techniques to evaluate changes
in SG size/activities, thus hoping to improve the inter-observer
reproducibility of published histological data, for example in trials
of SG disorders (31). The techniques described here are transfer-
able to isolated/specialised SGs and are relevant to other SG
research models, for example hamster SGs and cultured sebocytes
(24,25,32).
Overview of SG biology
Sebaceous glands are prominent in the skin of most mammals,
including humans and rodents. Most SGs are located in the mid-
dermis in association with a hair follicle, into whose (follicular)
canal the sebaceous duct inserts, thus forming an integral part of
the pilosebaceous unit. Just as other skin appendages, most
notably the hair follicle, the SG is supported and surrounded by a
dense, collagen-rich stroma (18), for which we propose, in analogy
to the hair follicle stroma, the term ‘SG connective tissue sheath’
(SG-CTS). In some regions, the pilosebaceous unit is comple-
mented by the apocrine gland (18,29,33), whose duct inserts into
the follicular canal above that of the SG (Fig. 1). In mice, the first
sebocytes of the SG begin to appear at stage 5 of hair follicle
morphogenesis (approximately days 34 post-partum in non-
guard pelage hair follicles) and begin to form the SG at morpho-
genesis stage 6 around one day later. By stage 7, the SG is
enlarged and begins to produce sebum (usually, this is achieved
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by day 5 post-partum) (34). Only in selected regions of human
skin, SGs are connected directly to the epidermal surface
(18,21,28) (see the Supporting Information for further details).
Free SGs are also found in pheromone-producing rodent preputial
glands (29).
Although previously presumed to be an ‘atavistic’ structure
with ‘absent, unimportant or unrecognisable’ functions in man
(35) or ‘a living fossil with a past but no future’ (36), there is
now compelling evidence to the contrary. The SG plays important
roles in skin barrier function, immunomodulation, antimicrobial
peptide production, lipid metabolism and various signalling
pathways within the skin, including steroid and peptide hormone
synthesis and metabolism (48,14,17,20,28,29,31,3751).
Just as the hair follicle epithelium (52), the SG may even have
established a functional hypothalamus-pituitary-adrenal (HPA) axis
equivalent (29), which mimics aspects of the cutaneous HPA axis
equivalent (53). For example, evidence of proopiomelanocortin,
b-endorphin and corticotrophin-releasing-hormone signalling
pathways has been reported in both the hair follicle and SG (54
57). These examples substantiate the hypothesis of a functional skin
HPA axis equivalent proposed in 1996 (58). Furthermore, the SG
and its SG-CTS harbour important immunocytes, for example Lan-
gerhans cells, macrophages and T cells (18,59) as well as different
progenitor cell populations (23,60). Contrary to the popular belief
that SGs are scarcely innervated (18), more recent research has
shown that SGs can show rich sensory innervation, namely in facial
skin and acne patients (61).
Sebocytes
The predominant constituent cell population of the SG is the seb-
ocyte, whose most recognised role is the production of sebum.
Within skin epithelium, sebocytes are easily identified by their
large size and ‘foamy’ appearance (Fig. 2) resulting from the pro-
duction of intracellular lipid droplets (18,62). Having developed
early during hair follicle morphogenesis, from intrafollicular epi-
thelial progenitor cells (22,34), relatively undifferentiated sebocytes
in mature SGs are located in the outermost layer (peripheral
zone), which shows the highest proliferative activity (Fig. 3). Mov-
ing towards the centre of the SG, the maturation zone contains
Figure 1. The Pilosebaceous Unit. The pilosebaceous unit consists of the hair
follicle, the sebaceous gland, and in some regions, the apocrine gland. When in
association with a hair follicle, sebum is secreted from the sebaceous gland to the
cell surface via the sebaceous duct and follicular canal. Key: AG, Apocrine Gland;
APM, Arector Pili Muscle; DP, Dermal Papilla; HS, Hair Shaft; SD, Sebaceous Duct;
SG, Sebaceous Gland; SG-CTS, Sebaceous Gland Connective Tissue Sheath. To
view the full-page figure, please see the Supporting Information.
(A) (B) (C) (D)
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Figure 2. Histochemical Stains for Analysis of the Sebaceous Glands.
Histochemical staining of the SG in humans and mice. Oil Red O staining and
Sudan Black B staining require the use of cryosections  paraffin sections are not
appropriate for these staining techniques. Note that with the Oil Red O and Sudan
stains, distinguishing individual cells is difficult, and that staining intensity of sebum
within the sebaceous duct is often stronger than the sebocytes within the gland
(image E). Key: HF, Hair follicle; SC, Subcutis; SD, Sebaceous duct; SG, Sebaceous
gland. (A) Haematoxylin & Eosin, human; (B) Haematoxylin & Eosin, mouse; (C)
Periodic Acid-Schiff, human; (D) Periodic Acid-Schiff, mouse; (E) Oil Red O, human;
(F) Oil Red O, mouse; (G) Sudan Black B, human; (H) Sudan Black B, mouse; (a)
sebocyte membrane highlighted with PAS; (b) SG basement membrane highlighted
with PAS; (c) SG-CTS highlighted with PAS. Scale bars: A, CD, FH = 50 lm;
B = 10 lm; E = 200 lm. To view the full-page figure, please see the Supporting
Information.
Figure 3. Schematic Representation of Sebaceous Gland Structure and of the
Various Staining Patterns Achieved by (Immuno)histochemistry. The sebaceous
gland contains sebocytes of varying degrees of differentiation, with the outermost
cell layer comprised of proliferating sebocytes, followed by maturing,
differentiating sebocytes that acquire increasing numbers of lipid droplets; the
central SG lobule then contains the fully differentiated/mature sebocytes
undergoing holocrine secretion. Various staining patterns may be obtained when
staining the SG by (immuno)histochemistry, namely nuclear, membranous,
cytoplasmic or whole gland staining patterns (shown in purple). Green arrows
represent the area to be included when measurements of gland area/sebocyte area
are performed. Key: FC, Follicular Canal; MZ, Maturation Zone; NZ, Necrosis Zone;
PZ, Peripheral Zone; SD, Sebaceous Duct; SG-CTS, Sebaceous Gland Connective
Tissue Sheath; SPC, Staining Pattern Cytoplasmic; SPM, Staining Pattern
Membranous; SPN, Staining Pattern Nuclear; SPW, Staining Pattern Whole gland;
black arrow- direction of sebum flow from sebaceous duct to skin surface. To view
the full-page figure, please see the Supporting Information.
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differentiating sebocytes, as evidenced by increasing numbers of
intracellular lipid droplets (63). Sebocyte proliferation and differ-
entiation are under tight hormonal control (e.g. stimulation by
androgens and prolactin; inhibition by oestrogens and some vanil-
loids (7,27,38)) and are governed by selected protein kinase C iso-
forms (64) and peroxisome proliferator-activated receptor-
mediated signalling (6567). The centre of the gland forms the
necrosis zone, containing terminally differentiated (mature) sebo-
cytes. These are lipid-laden and feature pyknotic nuclei before cell
rupture and dispersion of the cell contents, completing the process
of holocrine secretion (2022), a unique method of secretion
employed by the SG (21,27). The mechanisms of holocrine secre-
tion are still hypothetical, but include the lysis of sebocytes by
hydrolytic enzymes within lysosomes (18), apoptosis-induced cell
lysis (68) and/or the release of sebum via an ABCB1 transporter-
dependent mechanism (24,25).
Sebum
The constituents of sebum are varied and include cell debris, vari-
ous lipids (44,69) (Table S1), antimicrobial peptides, free fatty
acids and histone H4 (43,46). In patients with acne vulgaris, it
also contains matrix metalloproteinases (70).
Sebum is deposited onto the skin surface via the sebaceous duct
and when associated with a hair follicle, the outwardly moving hair
shaft serves as a wick that facilitates sebum dispersion (71) (Fig. 1).
Once secreted, sebum forms the skin surface lipid film, providing a
protective barrier against external insults (18,20,21,28,39).
Relevance in clinical dermatology
Acne vulgaris is the classic disease associated with SG dysfunction
(13,27,31,7275). The SG may also be involved in other disor-
ders, for example the pathogenesis of cicatricial alopecia (7678)
and of chemotherapy-induced alopecia (79). Whilst they rarely
give rise to benign/malignant tumors (a distinctive feature of
Muir-Torre syndrome) (20,8083), SG hyperplasia is a frequently
encountered cosmetic nuisance (84).
An ever-increasing number of mouse mutants is being described
that display a SG phenotype (22,39,76,8587), suggesting that the
range of skin disorders associated with SG dysfunction is wider
than currently appreciated, possibly including androgenetic
alopecia (20,8890). Many of these conditions can be instructively
studied using histological/immunohistological techniques. Thus,
there are multiple biological and clinical reasons to develop a stan-
dardised methodology for assessing SGs in situ in humans and
mice.
Practical considerations: Choosing the correct tissue
processing and SG read-out parameters
When beginning any analysis of the SG, one must consider appro-
priate tissue processing, that is, cryo- versus paraffin embedding.
Although paraffin-embedded tissue provides excellent morphologi-
cal detail, the subsequent de-paraffinisation process removes SG
lipids, and consequently, crucial lipid histochemical stains, for
example Oil Red O, can no longer be performed. Therefore,
cryosections are more versatile for SG analysis.
One particularly instructive analysis method that is now com-
monly employed in murine SG research is the epidermal whole
mount technique (23,91,92). Used in conjunction with confocal
microscopy, it provides excellent morphological detail of the SG,
whilst maintaining tissue integrity and allows three-dimensional
visualisation and measurement of the SG in situ in a large cutane-
ous field (this can be complemented with immunohistochemistry,
with the number of markers which can be analysed within one
sample being limited by the number of colour channels available).
Another major consideration is the selection of appropriate read-
out parameters. In Table 1, we describe some of the frequently
employed immunohistochemical (IHC) and immunofluorescent
(IF) markers of differentiating sebocytes/sebocyte progenitor cells.
In Table 2, we suggest some of the in situ techniques, which may
be employed to address frequently asked, specific SG research
questions. Used together, these tables provide detailed information
on which commonly used markers of sebocytes and SGs are
available, and on the conditions under which these may best be
utilised.
Visualising the SG by routine histochemistry
Routine haematoxylin and eosin (H&E) histochemistry remains
the mainstay of SG visualisation. In murine and human skin,
sebocytes stand out as the largest intradermal cells with a ‘foamy’
phenotype (Fig. 2). H&E clearly outlines all components of the
SG, its position within the skin, and the insertion of its duct into
the hair follicle epithelium. This can be complemented by periodic
acid-schiff (PAS) histochemistry, highlighting a) sebocyte mem-
branes, b) the SG basement membrane zone, and c) the surround-
ing SG-CTS (Figs. 2C, D).
Giemsa and/or toluidine blue histochemistry offer a straightfor-
ward assessment of the inflammatory cell infiltrate within/around
the SG. Where needed, this can then be followed up by immuno-
histology for the appropriate cluster of differentiation antigens
(see e.g. 59). Due to space constraints, the current guide only
covers sebocyte-related IHC/IF markers.
Basic quantitative morphometry of the SG
Because the SG is a multi-lobulated structure comprising sebocytes
in several distinct stages of differentiation (18,22,63,93), there are
limits to how well the SG can be visualised and quantified by two-
dimensional morphometric techniques. Where confocal microscopy
or three-dimensional ultrasound microscopy (94,95) are unavailable,
standard morphometric techniques can only yield approximations
of SG architecture. With this important caveat in mind, routine
H&E histology can still provide instructive, quantitative data
(Figure S1).
Cell number, proliferation, apoptosis
Quantifying the average sebocyte number in H&E-stained SG
sections provides invaluable baseline data for subsequent in situ
analyses, which permit insights into altered sebocyte proliferation/
apoptosis. Cell numbers can also be very easily quantified by
counting 4,6-diamidino-2-phenylindole (DAPI)+ nuclei within
the SG (Figure S1). These data can then be followed up by, for
example Ki67 or terminal deoxynucleotidyl transferase dUTP nick
end labelling (TUNEL) immunohistochemistry (see below). If
alterations in SG lipid/antigen staining intensity are found without
corresponding changes in cell numbers, this can indicate an
altered sebocyte differentiation pattern.
SG volume/size
The overall size of the SG is a useful measure of gland stability,
that is, whether the test condition has resulted in, for example, SG
atrophy. If combined with cell number counts, SG hypertrophy
versus SG hyperplasia can be distinguished. SG planimetry, using
image analysis software, for example ImageJ (96), permits an esti-
mate of SG volume in lieu of three-dimensional techniques, by
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measuring multiple reference areas (Figure S1), ideally, on multi-
ple non-consecutive histological sections through the same gland
(Figures S2 and S3) or by assessing many different glands in the
same sample. Note that the number of glands per hair follicle and
SG size differs depending upon body location and hair follicle
type; therefore, analyses should compare like samples, for example
human sebaceous follicle-associated SGs should not be directly
compared with human terminal scalp or vellus hair associated
SGs. In mice, it is particularly important to distinguish SGs associ-
ated with guard (tylotrich) hair follicles, which normally carry two
SGs, from the majority of non-guard pelage hair follicles that dis-
play only a single SG (97).
Volume/size of individual sebocytes
Measuring changes in the volume/size of individual sebocytes is
another useful parameter, which gauges sebocyte differentiation.
An increase in cell area (and therefore likely cell volume) may
suggest progression of differentiation, which is usually associated
with an increase in sebum production (Fig. 3 and Figure S1).
Sebocyte size measurements should be performed on a large
number of mature, differentiated sebocytes with clearly visible
nuclei. Importantly, inhibition of lipogenesis does not lead to
shrinkage of fully differentiated sebocytes. Rather, reduced lipogen-
esis inhibits the differentiation of small, basal sebocytes, increasing
the number of undifferentiated and reducing the number of differ-
entiated sebocytes, thus eventually reducing the volume of the
entire SG (63).
Whilst H&E suffices to assess sebocyte volume, PAS histochem-
istry and mucin-1 (MUC1)/milk fat globulin immunohistochemis-
try demarcate the cell boundary of sebocytes in situ even more
sharply.
SG histochemistry
Other important histochemical stains for SG visualisation are Oil
Red O (28,98), which demarcates neutral lipids, for example
triglycerides, and Sudan Black B, which stains all lipids (Fig. 2).
Clinically, these stains allow one to identify cancers of sebaceous
origin (e.g. use of Oil Red O to identify metastatic sebaceous
gland carcinoma in lymph nodes (99); Sudan Black B for diagnos-
ing sebaceous adenoma of the palate (83)).
Nile Red staining is also employed in SG research (22,98),
enabling both neutral and polar lipids to be distinguished within
the same specimen using different excitation and emission filters.
When dissolved in neutral lipids, for example triacylglycerol, Nile
Red will fluoresce yellow-gold (485 nm excitation and 565 nm
emission filters); whereas in phospholipids, for example phospha-
tidylcholine, Nile Red will fluoresce red (494 nm excitation and
523 nm emission filters) (5,100,101).
Table 1. IHC/IF markers of differentiating sebocytes or sebocyte progenitor cells
Marker Alternative Names Type of Molecule Description References
Mucin-1 (MUC1) Epithelial membrane
antigen (EMA)
Polymorphous epithelial
sialomucin (PEM)
Highly glycosylated, high MW glycoproteins
expressed at cell surface or released as secretory
product. Functions include hydration, lubrication
and antimicrobial defense
(22, 112117)
MAM-6c Not applicable Polymorphous epithelial
sialomucin (PEM)
Highly glycosylated, high MW glycoproteins
expressed at cell surface or released as secretory
product. Functions include hydration, lubrication
andantimicrobial defense
(63, 112, 115)
Human Milk Fat Globulin 2
(HMFG2)
Not applicable Milk Fat Globulin Highly glycosylated, high MW glycoproteins (63, 112, 113, 115, 118)
Ovarian-Carcinoma-
Associated Sebaceous
Gland Antigen (SGA)
Not applicable Milk Fat Globulin Highly glycosylated, high MW glycoproteins (63, 112, 113, 115, 118)
Keratin 7 (K7) Cytokeratin 7 (CK7) Keratin Present in human (but absent in mouse) SG (22, 63, 115, 119, 120)
Perilipin 2 Adipophilin; Adipose
differentiation-related
protein (ADRP)
Perilipin Lipid droplet-associated protein. First identified in
adipocytes but since shown to be present in
sebocytes
(21, 22, 60, 121125)
Fatty Acid Synthase (FASN) Not applicable Enzyme involved in
lipogenesis
Synthesises long-chain fatty acids that are present
in human and murine sebum
(21, 22, 28, 44, 126)
Stearoyl-Coenzyme A
desaturase 1 (SCD1)
Not applicable Enzyme involved in
fatty acid metabolism
Catalyses the D-9-cis desaturation of saturated
fatty acids. Involved in sebocyte differentiation,
lipogenesis and lipid metabolism. Essential for SG
maintenance.
(22, 60, 85, 127130)
Indian Hedgehog (IHH) Not applicable Hedgehog signalling
protein
Important during foetal SG development. Promotes
proliferation of undifferentiated sebocyte
precursors
(131135)
Peroxisome proliferator-
activated receptor
gamma (PPARc)
Not applicable Nuclear hormone
receptor
Acts as transcriptional regulator of genes involved
in lipid metabolism. Loss in the hair follicle bulge
induces SG atrophy
(111, 136138)
Melanocortin 5 receptor
(MC5R)
Not applicable G-protein coupled
receptor
Present in SG. Inhibition causes reduction in
differentiation and reduction in production of
squalene and wax esters
(47, 139141)
Leucine-rich repeats and
immunoglobulin-like
domain protein 1 (Lrig1)
Not applicable Transmembrane protein
(receptor antagonist)
Suppresses signalling by ErbB growth factor
receptors. Marker of multipotent stem cells.
Lrig1 positive cells may act as sebocyte
progenitors under homoeostatic conditions
(22, 60, 142144)
PR domain-containing
protein 1 (PRDM1)*
B-lymphocyte-induced
maturation protein 1
(BLIMP1)
Transcriptional repressor
(transcription factor)
Possible marker of sebocyte progenitor cells* (137, 145)
*PRDM1 as a marker of sebocyte progenitor cells is contested by some (see (23, 146, 147)). To view the full-page table, please see the Supporting Information.
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With the exception of Nile Red staining, these techniques
require little in the way of specialist equipment, and thus offer
particularly useful read-out parameters.
Quantitative analysis of specific SG histochemistry
Quantitative analysis of histochemical SG stains, for example Oil
Red O, routinely requires the use of image analysis software, such
as ImageJ. As the SG will often be intensely stained, demarcation
of specific areas/cells of the SG is difficult (Fig. 2). In these cases,
the relative staining intensity of the SG area can be calculated. To
reduce investigator bias, the whole SG area, using the SG-CTS as
an outline and the beginning of the sebaceous duct as a cut-off
point, should be measured for staining intensity (preferably on
several non-consecutive sections) (Figure S1).
Immunohistochemical (IHC)/immunofluorescent (IF)
SG markers
Several instructive IHC and IF techniques are available for study-
ing SGs. These techniques not only localise the expression of
defined antigens to specific cells within/around the SG, but also
permit functional studies on sebocyte proliferation/apoptosis. We
have selected several IHC markers of differentiating sebocytes/sebo-
cyte progenitor cells (Table 1) that we consider to be most useful
in SG research (see also Fig. 4). Note that not all of these markers
are relevant to both humans and mice (see Table 2), and that spe-
cies-dependent differences need to be taken into account. For guid-
ance on which typically asked SG research questions can be best
answered by employing which specific markers, consult Table 2.
Studying SG proliferation and apoptosis in situ
General markers for proliferation/apoptosis should be routinely
incorporated into SG research in situ to complement the basic cell
count and SG size data. Due to the distinctive compartmental lo-
calisation and highly characteristic morphology of sebocytes, it is
easy to restrict the quantitative assessment of standard prolifera-
tion/apoptosis markers exclusively to sebocytes. Proliferation/
apoptosis in the SG-CTS should strictly be regarded separately
from that of sebocytes.
Table 2. Choosing SG read-out parameters
Which technique is best employed for visualising
the SG when my main focus is the following…?
Appropriate staining
technique(s)
Species
Specificity
Antigen/Target
Location
Analysis
Technique(s) References
Sebaceous gland and sebocyte microanatomy
and morphometry
H&E H M N/A ACN; ACS; AGA (63, 93)
Sebum distribution using a light microscope,
specifically focussing on neutral lipids such as
triglycerides and cholesterol esters
Oil Red O H M Cytoplasm AGA; SI (21, 98, 115)
Sebum distribution using a light microscope,
highlighting all lipids
Sudan Black B H M Cytoplasm AGA; SI (62, 83)
Sebum distribution using fluorescence microscopy,
with the ability to distinguish neutral from polar lipids
Nile Red H M Cytoplasm AGA; SI (98, 100, 101)
Enzymatic activity within the SG Alkaline Phosphatase H M Cytoplasm AGA; SI (148)
Expression of markers of differentiating/
differentiated sebocytes using immunohistochemistry
MUC1, MAM6c,
HMFG2, SGA
H Membrane ACN; ACS,
AGA; ECP; SI
(63, 112, 113, 115, 118, 149)
Expression of essential structural proteins of sebocytes
using immunohistochemistry
Keratin 7 H Cytoplasm ACN; ACS;
AGA; ECP; SI
(63, 115, 119, 150)
Lipid droplet presence and conformation in
sebocytes using immunohistochemistry
Perilipin 2 H M Lipid Droplet
Membrane
ACN; ACS; AGA,
ECP; SI
(21, 122, 124)
Levels of key enzymes involved in lipid metabolism
of sebocytes using immunohistochemistry
Fatty Acid Synthase
SCD1
H M
H M
Cytoplasm
Cytoplasm
ACN; AGA; SI
ACN; AGA; SI
(21, 85, 130)
Levels of developmental proteins involved in
the proliferation and differentiation of
sebocytes using immunohistochemistry
Indian Hedgehog H M Membrane/
Excreted
ACN; ACS;
AGA; ECP; SI
(132, 134)
Numbers of cells undergoing proliferation
using immunohistochemistry
Ki67
BrdU
EdU
H M
H M
H M
Nucleus
Nucleus
Nucleus
ACN; AGA; ECP
ACN; AGA; ECP
ACN; AGA; ECP
(151, 152)
Numbers of cells undergoing apoptosis
using immunohistochemistry
TUNEL
Caspase 3
H M
H M
Nucleus
Cytoplasm
ACN; AGA; ECP
ACN; AGA; ECP
(68, 153)
H, human; M, murine.
ACN, average cell number; ACS, average cell size; AGA, average gland area; ECP, expressing cell percentage; SI, staining intensity. To view the full-page table, please
see the Supporting Information.
(A) (B) (C) (D) (E)
(F) (G) (H) (I) (J)
Figure 4. Immunohistochemical Stains for Analysis of the Sebaceous Glands.
Various immunohistochemical stains are available for analysis of the sebaceous
glands. We have highlighted the markers that we feel are the most instructive
however, this list is not exhaustive. Note that image H represents healthy tissue
and therefore the presence of apoptotic cells within the SG is a very infrequent
event. Nevertheless, apoptotic cells can still be seen surrounding the gland,
highlighting the sensitivity of the TUNEL method for detecting apoptotic cells.
Dashed lines indicate the peripheral zone of the sebaceous gland. Key: HF, hair
follicle; SD, sebaceous duct; SG, sebaceous gland; SG-CTS, Sebaceous Gland
Connective Tissue Sheath; (A) Mucin1, human; (B) Keratin 7, human; (C)
Peroxisome proliferator-activated receptor gamma, human; (D) Perilipin 2, mouse;
(E) OM-1 antigen, human; (F) Fatty Acid Synthase, human; (G) Indian Hedgehog,
human; (H) Ki67/TUNEL, human; (I) EdU, human; (J) Leucine-rich repeats and
immunoglobulin-like domain protein 1, mouse. Scale bars: AB, D, FI = 50 lm; C,
E, J = 200lm. To view the full-page figure, please see the Supporting Information.
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Proliferation markers: Ki67, BrdU, EdU
Ki67 is a well-established proliferation marker that highlights cells
which have entered the cell cycle (102). However, Ki67 does not
provide unequivocal evidence of actual proliferation or mitosis.
Light microscopically, the latter can be assessed by counting the
number of mitotic figures after colchicine-induction of mitotic
spindle arrest (ideally, in iron haematoxylin stains (103)), or
by more in-depth immunofluorescent cell cycle and DNA synthe-
sis analyses in situ (e.g. 104,105), although these remain to
be systematically applied to SG research. In human and murine
skin, analysis of Ki67 immunoreactivity is best complemented by
determining the number of sebocytes that actively synthesise DNA
in situ, by measuring the incorporation of bromodeoxyuridine
(BrdU) or 5-Ethynyl-2-deoxyuridine (EdU) (Fig. 4I,  see
Supporting Information for details).
Apoptosis markers: TUNEL, cleaved caspase 3
Apart from ultrastructural techniques, TUNEL immunohistochem-
istry offers a simple method for detecting changes in sebocyte
apoptosis. However, the TUNEL technique has its limitations
in that it can give false-positive results, for example in terminally
differentiating epithelial cells (for discussion, see 106). Therefore,
it is advisable to complement TUNEL data with additional
methods (e.g. cleaved caspase 3  for details, see Supporting
Information) (Fig. 4).
Quantitative immunohistomorphometry
All of the IHC/IF read-out parameters listed above should be
assessed by quantitative immunohistomorphometry so as to gener-
ate robust, standardised and reproducible data. The methods
described above (sebaceous gland size, sebocyte size, cell number,
staining intensity) can all be incorporated into analysis of IHC/IF
markers, as well as the percentage of antigen-expressing cells (for
further information on standardised quantitative immuno-
histomorphometry techniques, see Supporting Information).
Summary
Here, we have discussed the use of routine histochemistry and
immunohistochemistry in the visualisation and quantitative assess-
ment of human and murine SGs in situ. Whilst, due to space
constraints, in vitro methods of sebocyte isolation, culture and
analysis cannot be discussed here, many of the markers and
techniques described here are also relevant for isolated primary
sebocytes and sebocyte cell lines (for methodological details, see
(98,107,108)). The techniques described can be complemented
with, for example double-immunofluorescence stains, laser capture
microdissection or lipidomics to provide an in-depth assessment
of the SG and can be utilised in both clinical studies and labora-
tory analyses. Such standardised (immuno-) histomorphometric
SG assessment criteria for evaluating therapeutic outcomes would
have been useful in past studies (e.g. 63,64,109111), where some-
times arbitrary or insufficiently defined/standardised SG read-out
parameters were employed. Routine use of the assessment criteria
and techniques suggested here should greatly facilitate the repro-
ducibility and standardisation of read-out parameters and assess-
ment techniques employed in future clinical SG-related trials, thus
standardising SG evaluation methods.
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the online version of this article:
Figure S1. How to Perform Analysis using ImageJ.
Figure S2. Sebaceous gland size measurements using
various planes of the same gland.
Figure S3. Area of 2 SG within the same skin sample
over a number of sections.
Table S1. Normal sebum composition of humans
and mice.
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